` TLX (Telix Pharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

TLX
vs
S&P/ASX 300

Over the past 12 months, TLX has significantly outperformed S&P/ASX 300, delivering a return of 36% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
TLX vs S&P/ASX 300

Loading
TLX
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
TLX vs S&P/ASX 300

Loading
TLX
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
TLX vs S&P/ASX 300

Loading
TLX
S&P/ASX 300
Add Stock

Competitors Performance
Telix Pharmaceuticals Ltd vs Peers

S&P/ASX 300
TLX
ABBV
AMGN
GILD
VRTX
Add Stock

Telix Pharmaceuticals Ltd
Glance View

Economic Moat
Wide
Market Cap
8.3B AUD
Industry
Biotechnology

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
22.33 AUD
Overvaluation 10%
Intrinsic Value
Price
Back to Top